The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

Researchers evaluated a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear ...

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...

In mid-2024, the commercial president of Pfizer’s oncology unit Suneet Varma announced his retirement after 15 years with the ...

A Huntsville-based biotechnology company has secured $10 million in funding to begin the trial of a new way to deliver medication to advanced Parkinson’s disease patients.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Pfizer shares are moving higher on Wednesday as the sector sees volatility amid Robert F. Kennedy Jr.'s nomination as the secretary of the Department of Health and Human Services.

The deal was signed with the Energize programme, a renewable energy purchasing vehicle for pharmeceutical companies.

BMS acquired Cobenfy as part of its $14 billion takeover of Karuna Therapeutics towards the end of 2023, and analysts at ...

A phase 3 study demonstrated that ritlecitinib was effective and well tolerated in patients with alopecia areata and ≥ 25% ...

BMS is not the only U.S. pharma giant making massive cuts. Last year, Pfizer revealed a similar plan to reduce $1.5 billion ...